Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04318080 · ClinicalTrials.gov registry record · Phase 2
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
A Phase 2 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT04318080 is a Phase 2 study that has completed, run by BeiGene. The registered enrollment target is 46 participants.
The verdict
NCT04318080, a Phase 2 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This was a Phase 2 trial evaluating the effectiveness and safety of tislelizumab in participants with relapsed or hard-to-treat classical Hodgkin lymphoma (cHL). Participants were grouped by prior treatments. The main outcome was to assess overall response rate (ORR) across both cohorts. Participants continued receiving the study treatment until their disease got worse, side effects became too severe, or they chose to stop for other reasons.
Interventions
- DRUG Tislelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2020-08-20 |
| Est. Completion | 2024-08-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04318080
The ClinicalTrials.gov registry entry for NCT04318080 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tislelizumab is the first listed.
NCT04318080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04318080 about?
NCT04318080 is a clinical study titled "Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma". This was a Phase 2 trial evaluating the effectiveness and safety of tislelizumab in participants with relapsed or hard-to-treat classical Hodgkin lymphoma (cHL). Participants were grouped by prior treatments. The main outcome was to assess overall response rate (ORR) across both cohorts. Participant...
What is the current status of trial NCT04318080?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2020-08-20. Estimated completion is 2024-08-29.
What interventions are being tested in trial NCT04318080?
The interventions under investigation include: Tislelizumab (DRUG).
Who is sponsoring clinical trial NCT04318080?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.